These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 30763190)

  • 1. Universal Medicine Access through Lump-Sum Remuneration - Australia's Approach to Hepatitis C.
    Moon S; Erickson E
    N Engl J Med; 2019 Feb; 380(7):607-610. PubMed ID: 30763190
    [No Abstract]   [Full Text] [Related]  

  • 2. Brazil's Fight against Hepatitis C - Universalism, Local Production, and Patents.
    da Fonseca EM; Shadlen K; Bastos FI
    N Engl J Med; 2019 Feb; 380(7):605-607. PubMed ID: 30763192
    [No Abstract]   [Full Text] [Related]  

  • 3. Campaigners challenge patent applications for hepatitis C drug in five countries.
    Bagcchi S
    BMJ; 2015 Jun; 350():h2938. PubMed ID: 26032985
    [No Abstract]   [Full Text] [Related]  

  • 4. Access to HCV treatments: hurdles not barriers.
    The Lancet Gastroenterology Hepatology
    Lancet Gastroenterol Hepatol; 2017 Jan; 2(1):1. PubMed ID: 28404005
    [No Abstract]   [Full Text] [Related]  

  • 5. Eliminating innovation: how price controls limit access.
    Ingram J
    J Leg Med; 2011 Jan; 32(1):115-28. PubMed ID: 21391059
    [No Abstract]   [Full Text] [Related]  

  • 6. Access to medicines and hepatitis C in Africa: can tiered pricing and voluntary licencing assure universal access, health equity and fairness?
    Assefa Y; Hill PS; Ulikpan A; Williams OD
    Global Health; 2017 Sep; 13(1):73. PubMed ID: 28903757
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rationing hepatitis C treatment in the context of austerity policies in France and Cameroon: A transnational perspective on the pharmaceuticalization of healthcare systems.
    Chabrol F; David PM; Krikorian G
    Soc Sci Med; 2017 Aug; 187():243-250. PubMed ID: 28392011
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Australia's pharmaceutical cost sharing policy: reducing waste or affordability?
    Doran E; Robertson J
    Aust Health Rev; 2009 May; 33(2):231-40. PubMed ID: 19563311
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Access to hepatitis C medicines.
    Edwards DJ; Coppens DG; Prasad TL; Rook LA; Iyer JK
    Bull World Health Organ; 2015 Nov; 93(11):799-805. PubMed ID: 26549908
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of generic medications for hepatitis C.
    Freeman JA; Hill A
    Liver Int; 2016 Jul; 36(7):929-32. PubMed ID: 27306303
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatitis C treatment in Guatemala: the struggle for access.
    Webster P
    Lancet; 2018 Jul; 392(10144):269-270. PubMed ID: 30064642
    [No Abstract]   [Full Text] [Related]  

  • 12. Importation of generic hepatitis C therapies: bridging the gap between price and access in high-income countries.
    Ghinea N; Lipworth W; Day R; Hill A; Dore GJ; Danta M
    Lancet; 2017 Mar; 389(10075):1268-1272. PubMed ID: 27832868
    [No Abstract]   [Full Text] [Related]  

  • 13. The Need to Expand Access to Hepatitis C Virus Drugs in the Indian Health Service.
    Leston J; Finkbonner J
    JAMA; 2016 Aug 23-30; 316(8):817-8. PubMed ID: 27228394
    [No Abstract]   [Full Text] [Related]  

  • 14. A pill too hard to swallow: how the NHS is limiting access to high priced drugs.
    Gornall J; Hoey A; Ozieranski P
    BMJ; 2016 Jul; 354():i4117. PubMed ID: 27469086
    [No Abstract]   [Full Text] [Related]  

  • 15. Crunching the numbers for viral hepatitis.
    The Lancet Gastroenterology Hepatology
    Lancet Gastroenterol Hepatol; 2021 Nov; 6(11):875. PubMed ID: 34626556
    [No Abstract]   [Full Text] [Related]  

  • 16. Gilead injects own generics into shrinking HCV drug market.
    Morrison C
    Nat Biotechnol; 2018 Nov; 36(11):1030. PubMed ID: 30412188
    [No Abstract]   [Full Text] [Related]  

  • 17. [Prescription of generic drugs to privately insured persons].
    Wild F
    Versicherungsmedizin; 2012 Dec; 64(4):190-2. PubMed ID: 23236709
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Limiting the access to direct-acting antivirals against HCV: an ethical dilemma.
    Gentile I; Maraolo AE; Niola M; Graziano V; Borgia G; Paternoster M
    Expert Rev Gastroenterol Hepatol; 2016 Nov; 10(11):1227-1234. PubMed ID: 27607920
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Indian hepatitis C drug patent decision shakes public health community.
    't Hoen EFM
    Lancet; 2016 Jun; 387(10035):2272-2273. PubMed ID: 27238944
    [No Abstract]   [Full Text] [Related]  

  • 20. Generic medications for hepatitis C.
    Jensen DM; Sebhatu P; Reau NS
    Liver Int; 2016 Jul; 36(7):925-8. PubMed ID: 27306302
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.